SCHEDULE: Franklin Advisers Reports 6.2% Stake in Contineum Therapeutics
Beneficial Ownership Report
Franklin Advisers, Inc., a subsidiary of Franklin Resources, Inc., has reported a 6.2% beneficial ownership stake in Contineum Therapeutics, Inc. Class A Common Stock.
Summary
- Franklin Resources, Inc. and its subsidiary, Franklin Advisers, Inc., along with Charles B. Johnson and Rupert H. Johnson, Jr., have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Contineum Therapeutics, Inc.
- Franklin Advisers, Inc. beneficially owns 1,879,367 shares of Contineum Therapeutics, Inc. Class A Common Stock, representing 6.2% of the class.
- Franklin Advisers, Inc. holds sole voting power and sole dispositive power over all 1,879,367 shares.
- Franklin Resources, Inc., Charles B. Johnson, and Rupert H. Johnson, Jr. are also listed as reporting persons but disclaim pecuniary interest in the reported securities, with Charles B. Johnson and Rupert H. Johnson, Jr. reporting 0% beneficial ownership.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by an institutional investor and does not indicate any significant change in strategy or financial performance for the issuer.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's stock, indicating passive investment intent. This filing updates the market on Franklin Advisers' continued significant, but non-controlling, stake in Contineum Therapeutics, aligning with standard portfolio management practices for large asset managers.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a passive investment approach.
- Company Management: Awareness of a large, passive institutional investor in their shareholder base.
Key Dates
| Date | Description |
|---|---|
| 2023-12-11 | Date of execution of Limited Powers of Attorney for Charles B. Johnson and Rupert H. Johnson, Jr. |
| 2025-12-31 | Date of event which requires the filing of this statement (end of reporting period). |
| 2026-01-26 | Date of signing and filing of the Schedule 13G Amendment No. 3. |
Keywords
Contineum Therapeutics, Franklin Advisers, Franklin Resources, Beneficial Ownership, Schedule 13G, Institutional Ownership, Investment Management, Class A Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.